HC Wainwright Has Optimistic Outlook of OKUR Q1 Earnings

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – Stock analysts at HC Wainwright lifted their Q1 2026 EPS estimates for shares of OnKure Therapeutics in a report issued on Monday, March 16th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($1.05) per share for the quarter, up from their prior estimate of ($1.15). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.88) EPS and FY2026 earnings at ($3.66) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last released its earnings results on Monday, March 9th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.16.

OKUR has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a report on Monday, December 22nd. Wall Street Zen upgraded OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $27.00.

OnKure Therapeutics Stock Up 9.1%

NASDAQ OKUR opened at $4.37 on Wednesday. The company has a 50-day simple moving average of $2.94 and a two-hundred day simple moving average of $2.90. OnKure Therapeutics has a 12-month low of $1.70 and a 12-month high of $5.11. The firm has a market cap of $59.27 million, a price-to-earnings ratio of -0.99 and a beta of 0.45.

Hedge Funds Weigh In On OnKure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of OnKure Therapeutics during the second quarter worth about $25,000. Jane Street Group LLC purchased a new position in OnKure Therapeutics during the 4th quarter valued at about $56,000. Rangeley Capital LLC bought a new position in OnKure Therapeutics during the 2nd quarter valued at approximately $71,000. Barclays PLC raised its position in OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after purchasing an additional 26,621 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in OnKure Therapeutics by 172.1% in the 3rd quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock worth $163,000 after buying an additional 37,459 shares during the period. 90.98% of the stock is owned by institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.